Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
-96.83%
↓ 126% below average
Average (39q)
367.46%
Historical baseline
Range
High:13779.78%
Low:-96.83%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -96.83% |
| Q2 2025 | 184.39% |
| Q1 2025 | -14.75% |
| Q4 2024 | -84.72% |
| Q3 2024 | 13779.78% |
| Q2 2024 | -25.99% |
| Q1 2024 | -76.44% |
| Q4 2023 | -78.27% |
| Q3 2023 | 37.50% |
| Q2 2023 | -95.67% |
| Q1 2023 | 480.08% |
| Q4 2022 | 2.91% |
| Q3 2022 | -9.93% |
| Q2 2022 | 4.06% |
| Q1 2022 | 0.88% |
| Q4 2021 | -2.02% |
| Q3 2021 | 2.48% |
| Q2 2021 | 6.06% |
| Q1 2021 | 1.86% |
| Q4 2020 | -55.33% |
| Q3 2020 | 168.00% |
| Q2 2020 | 64.83% |
| Q1 2020 | -76.16% |
| Q4 2019 | 149.80% |
| Q3 2019 | 25.13% |
| Q2 2019 | 117.42% |
| Q1 2019 | -69.93% |
| Q4 2018 | 13.90% |
| Q3 2018 | 10.02% |
| Q2 2018 | 69.47% |
| Q1 2018 | -3.36% |
| Q4 2017 | 10.71% |
| Q3 2017 | 43.12% |
| Q2 2017 | 140.96% |
| Q1 2017 | -61.61% |
| Q4 2016 | 216.05% |
| Q3 2016 | -23.74% |
| Q2 2016 | -6.09% |
| Q1 2016 | -56.78% |
| Q4 2015 | 6.44% |